Dr. Matis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
95 Chester Place
Southport, CT 06890Phone+1 203-521-2003
Education & Training
University of ChicagoResidency, Internal Medicine, 1975 - 1977
Perelman School of Medicine at the University of PennsylvaniaClass of 1975
Certifications & Licensure
CT State Medical License 1993 - 2022
MD State Medical License 1980 - 1993- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1991
Publications & Presentations
PubMed
- 1 citationsA First-in-Human Study of cinrebafusp alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies.Sarina Piha-Paul, Shane A Olwill, Erika Hamilton, Anthony Tolcher, Paula Pohlmann
Clinical Cancer Research. 2024-09-05 - 84 citationsTumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343Marlon Hinner, Rachida Siham Bel Aiba, Thomas Jaquin, Sven Berger, Manuela Carola Dürr
Clinical Cancer Research. 2019-10-01 - 104 citationsInducible costimulator regulates Th2-mediated inflammation, but not Th2 differentiation, in a model of allergic airway diseaseAmanda G. Tesciuba, Sumit K. Subudhi, Russell P. Rother, Susan J. Faas, Aric M. Frantz
Journal of Immunology. 2001-08-15
Press Mentions
Pieris Pharmaceuticals and AstraZeneca Present Single- Ascending Dose Phase 1a Data for Inhaled IL-4Rα Antagonist AZD1402/PRS-060 at the American Thoracic Society (ATS) 2019 International ConferenceMay 22nd, 2019
Pieris Pharmaceuticals Appoints Ingmar Bruns, M.D., Ph.D., as Vice President of Clinical DevelopmentOctober 12th, 2017
Pieris Signs 1st Partnership for Anemia Drug PRS-080, Granting Exclusive Option in Japan to ASKA PharmaceuticalFebruary 27th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
